Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines
Cancer Medicine · 2026-06 · 15 (6)
DOI: 10.1002/cam4.72007 ↗Kurz gefasst
Leitlinie in der Zeitschrift Cancer Medicine, online erschienen am 07.06.2026. Verfasst von Veronica Fitzpatrick und 6 weiteren Autor:innen. Beteiligte Einrichtung: Advocate Aurora Research Institute, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Down Syndrome, Neoplasms, Early Detection of Cancer. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Introduction
It is known that individuals with Down syndrome (DS) have a significantly different spectrum of malignancies and neoplasms. Research shows that most solid tumors are less common among individuals with DS compared to the general population, even when adjusted for age. Conversely, individuals with DS are more likely to develop leukemia and testicular cancer. However, very little of this research has been conducted with a US‐based population or on large sample sizes.
Methods
This retrospective cohort study analyzed 24 years of EHR data from 5895 unique individuals with DS seen in a Midwestern US health system, with the largest designated DS clinic in the US. We calculated the point prevalence of each cancer type, based on ICD‐10 coding, in our DS cohort, examined co‐occurrence patterns, and compared prevalence within our sample to the US general population using SEER data from 2022.
Results
Individuals with DS have significantly lower odds of cancer than the general population (OR = 0.88 (0.77–0.99)). Our cohort was 50.2% less likely to have skin cancer, 80.1% less likely to have cervical cancer, 91% less likely to have prostate cancer, and 90% less likely to have breast cancer. Zero people in our DS cohort had lung cancer. Conversely, our cohort was more likely to have leukemia and testicular cancer.
Conclusion
The differences in prevalences indicate a need to consider modification of the cancer screening recommendations for people with DS and inclusion of the information in shared‐decision making conversations with the patient and their family.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Advocate Aurora Research Institute, Milwaukee, Wisconsin, USA.
- Advocate Health Oak Brook Support Center, Oak Brook, Illinois, USA.
- Aurora Medical Group, Milwaukee, Wisconsin, USA.
- Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Advocate Medical Group Adult Down Syndrome Center, Park Ridge, Illinois, USA.
ORCID-Profile: Veronica Fitzpatrick, Akaninyene Noah, Brian Chicoine
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Fitzpatrick, V., Noah, A., Rivelli, A., Johnson, R., Zak, M., Espinosa, J., & Chicoine, B. (2026). Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.72007
Vancouver
Fitzpatrick V, Noah A, Rivelli A, Johnson R, Zak M, Espinosa J, et al. Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.72007
BibTeX
@article{Fitzpatrick2026,
author = {Fitzpatrick, Veronica and Noah, Akaninyene and Rivelli, Anne and Johnson, Rachel and Zak, Melissa and Espinosa, Joaquin and Chicoine, Brian},
title = {Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cam4.72007}
}
EUVIMED